Edgar Filing: ADVANCED CELL TECHNOLOGY, INC. - Form 8-K

ADVANCED CELL TECHNOLOGY, INC.

Form 8-K

August 09, 2011

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 1, 2011

ADVANCED CELL TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

000-50295 (Commission File Number)

87-0656515 (IRS Employer Identification Number)

33, LOCKE DRIVE, MARLBOROUGH, MASSACHUSETTS 01752

(Address of principal executive offices, including zip code)

(508)756-1212

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

Edgar Filing: ADVANCED CELL TECHNOLOGY, INC. - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective August 1, 2011 Erkki Ruoslahti, a Director of Advanced Cell Technology, Inc. (the "Company") resigned from the Board of Directors of the Company to focus full-time on his commercial opportunities. There was no disagreement between Dr. Ruoslahti and the Company on any matter relating to the operations, policies, or practices of the Company.

Edgar Filing: ADVANCED CELL TECHNOLOGY, INC. - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADVANCED CELL TECHNOLOGY, INC.

By: /s/GARY RABIN

Gary Rabin

Interim Chief Executive Officer

Dated: August 8, 2011